| scholarly article | Q13442814 |
| P2093 | author name string | Göran B Klintmalm | |
| Jacqueline G O'Leary | |||
| James F Trotter | |||
| Gary L Davis | |||
| Michael A Neri | |||
| P2860 | cites work | Boceprevir for previously treated chronic HCV genotype 1 infection | Q24620576 |
| Review and management of drug interactions with boceprevir and telaprevir | Q24628716 | ||
| Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection | Q27860901 | ||
| Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial | Q27860949 | ||
| Telaprevir for retreatment of HCV infection | Q29619799 | ||
| Telaprevir for previously untreated chronic hepatitis C virus infection | Q29619800 | ||
| The prevalence of hepatitis C virus infection in the United States, 1999 through 2002 | Q29619974 | ||
| Report of the first International Liver Transplantation Society expert panel consensus conference on liver transplantation and hepatitis C. | Q35572041 | ||
| The use of hepatitis C-infected grafts in liver transplantation | Q35572059 | ||
| Virologically compromised donor grafts in liver transplantation. | Q35908790 | ||
| Interleukin-28B polymorphisms are associated with histological recurrence and treatment response following liver transplantation in patients with hepatitis C virus infection | Q37329869 | ||
| Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials | Q42991080 | ||
| Outcome of liver transplantation in hepatitis C virus-infected patients who received hepatitis C virus-infected grafts | Q42993989 | ||
| Use of hepatitis C-infected donors for hepatitis C-positive OLT recipients | Q42995707 | ||
| Evaluation of a new, rapid test for detecting HCV infection, suitable for use with blood or oral fluid | Q43032401 | ||
| Boceprevir for chronic HCV genotype 1 infection | Q43038559 | ||
| Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy | Q43047921 | ||
| Zero risk tolerance costs lives: loss of transplantable organs due to human immunodeficiency virus nucleic acid testing of potential donors | Q45362748 | ||
| Long-term follow-up and outcome of liver transplantation from anti-hepatitis C virus-positive donors: a European multicentric case-control study. | Q45367497 | ||
| Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus | Q84208214 | ||
| P433 | issue | 8 | |
| P304 | page(s) | 825-829 | |
| P577 | publication date | 2012-05-30 | |
| P1433 | published in | Transplant International | Q15762140 |
| P1476 | title | Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determined | |
| P478 | volume | 25 |
| Q40600331 | Changes in Utilization and Discard of Hepatitis C-Infected Donor Livers in the Recent Era. |
| Q38720932 | Extended criteria donors in liver transplantation Part I: reviewing the impact of determining factors. |
| Q30251928 | Extended-criteria donors in liver transplantation Part II: reviewing the impact of extended-criteria donors on the complications and outcomes of liver transplantation. |
| Q92670166 | Recent advances in liver transplantation with HCV seropositive donors |
| Q38757351 | The American Society of Transplantation Consensus Conference on the Use of Hepatitis C Viremic Donors in Solid Organ Transplantation. |
| Q36292616 | Use of Hepatitis C-Positive Donor Livers in Liver Transplantation |
| Q90601550 | Use of Hepatitis C-Positive Liver Grafts in Hepatitis C-Negative Recipients |
Search more.